Siren L.L.C. Purchases Shares of 746,226 Enliven Therapeutics, Inc. $ELVN

Siren L.L.C. purchased a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 746,226 shares of the company’s stock, valued at approximately $29,252,000.

Other large investors have also recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at $334,000. Candriam S.C.A. increased its holdings in Enliven Therapeutics by 31.1% in the 1st quarter. Candriam S.C.A. now owns 594,079 shares of the company’s stock worth $23,288,000 after purchasing an additional 141,060 shares in the last quarter. Spruce Street Capital LP acquired a new position in Enliven Therapeutics in the 4th quarter worth about $6,870,000. Seven Fleet Capital Management LP bought a new position in Enliven Therapeutics in the fourth quarter valued at about $180,000. Finally, Capricorn Fund Managers Ltd bought a new position in Enliven Therapeutics in the first quarter valued at about $14,480,000. Institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the completion of the sale, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the transaction, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. This represents a 16.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock worth $1,113,888 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Enliven Therapeutics Trading Down 0.1%

Shares of ELVN stock opened at $52.81 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $54.88. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -31.62 and a beta of 0.24. The stock has a 50-day moving average of $45.26 and a 200-day moving average of $37.16.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

ELVN has been the topic of several research reports. JonesTrading boosted their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. The Goldman Sachs Group raised their price objective on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Mizuho boosted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Finally, HC Wainwright upped their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.